دورية أكاديمية
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT)
| العنوان: | Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT) |
|---|---|
| المؤلفون: | El Zarif, Talal, Nassar, Amin, Jiang, Lijuan, Pond, Gregory Russell, Zhuang, Tony, Velev, Maud, Hahn, Andrew Warren, Buti, Sebastiano, Álvarez, Pablo, McKay, Rana R., Vincenzi, Bruno, El-Am, Edward, Hui, Gavin, Lee, Jae-Lyun, Mouhieddine, Tarek H., Milowsky, Matthew I., Matthews, Harrison, Barata, Pedro C., Apolo, Andrea B., Sonpavde, Guru P. |
| المساهمون: | El Zarif, Talal, Nassar, Amin, Jiang, Lijuan, Pond, Gregory Russell, Zhuang, Tony, Velev, Maud, Hahn, Andrew Warren, Buti, Sebastiano, Álvarez, Pablo, Mckay, Rana R., Vincenzi, Bruno, El-Am, Edward, Hui, Gavin, Lee, Jae-Lyun, Mouhieddine, Tarek H., Milowsky, Matthew I., Matthews, Harrison, Barata, Pedro C., Apolo, Andrea B., Sonpavde, Guru P. |
| بيانات النشر: | ASCO pubs |
| سنة النشر: | 2023 |
| المجموعة: | Università di Parma: CINECA IRIS |
| الوصف: | Background: Management options for patients (pts) with advanced (locally advanced or metastatic) PeCa are limited. The GSRGT assembled an international cohort of pts with advanced PeCa treated with ICI to evaluate toxicity and clinical outcomes. Methods: We retrospectively collected data on pts with advanced PeCa receiving ≥1 cycle of ICI between 2015-2022 at 18 medical centers in the US, Europe, and Asia. Immune-related adverse events (irAE) were graded per the Common Terminology Criteria for Adverse Events v5.0. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan-Meier method. Objective response rate (ORR) was determined by the clinical investigator per RECIST 1.1 criteria, whenever feasible. Results: Among 72 pts with advanced PeCa treated with ICI, 24 (33%) were Hispanic and 7 (10%) were Black. 60 (83%) pts had metastases while the remainder had locally advanced disease. The median age was 64 (inter-quartile range (IQR): 54,70) years and 48 (67%) had ECOG performance status ≥1. Most pts (n=60, 83%) were treated in the ≥2nd line setting and received pembrolizumab (n=23), nivolumab (n=15), cemiplimab (n=15), nivolumab and ipilimumab (n=7), or other anti-PD1/L1-based therapies (n=12). Among 37 pts with available data on HPV status, 24 (65%) were HPV+. 3 (4%) pts were HIV+. irAE of any grade occurred in 18 (25%) pts, 7 (10%) were grade ≥3, 7 (10%) required steroids, 6 (9%) required hospitalization, and 8 (11%) led to treatment discontinuation. The median OS and 24-month OS and median PFS and 24-month PFS were 9.4 (95%CI: 6.8, 12.8) months and 19.3% (95%CI: 9.2, 32.1) and 2.8 (95%CI: 2.1, 3.9) months and 11.2 % (95%CI: 4.9, 20.2), respectively. Among 66 pts evaluable for response, ORR was 7/66 (11%) (2 with complete response, 5 with partial response), and 16 (24%) pts had stable disease for a disease control rate of 35%. The median duration of response was 7.9 (IQR: 3, not reached) months. Conclusions: In the largest retrospective cohort of ICI-treated advanced PeCa, ICI showed ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | volume:41; issue:6_suppl; firstpage:5; lastpage:5; numberofpages:1; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/11381/2944131Test |
| DOI: | 10.1200/JCO.2023.41.6_suppl.5 |
| الإتاحة: | https://doi.org/10.1200/JCO.2023.41.6_suppl.5Test https://hdl.handle.net/11381/2944131Test |
| رقم الانضمام: | edsbas.996A2C6D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1200/JCO.2023.41.6_suppl.5 |
|---|